Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Boehringer Ingelheim Bolsters Biologics R&D With Big Investment

By Catherine Sbeglia | June 25, 2018

Boehringer Ingelheim will invest nearly $270 million into a new Biologicals Development Center (BDC). The center will be located at the company’s research and development site in Biberach, Germany. The new center is expected to increase development capacity for biologics, and according to Corporate Senior Vice President Development at Boehringer Ingelheim, Dr. Fridtjof Traulsen, biological entities now account for forty percent of the company’s research pipeline. 

Earlier this year, Boehringer Ingelheim announced its intent to invest $23.3 billion into research and development and at the same time, it set out to submit 15 new drugs for approval by 2025. The BDC appears to be a significant step towards this goal, with Dr. Fridtjof Traulsen commenting, “The [center] is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology.” 

Boehringer Ingelheim plans for the BDC to integrate biologicals analytical and process development as well as manufacturing for clinical studies into a single unit, maximizing synergies. The new center will require 500 employees, an increase of about 100 in biological development compared to today. 

(Source: Boehringer Ingelheim)

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE